95 related articles for article (PubMed ID: 2135063)
1. [Evaluation of the advantage of determination of urinary pseudouridine for the early detection of a malignant transformation process].
Senden D; Buchet JP; Lauwerys R
J Toxicol Clin Exp; 1990; 10(7-8):473-80. PubMed ID: 2135063
[TBL] [Abstract][Full Text] [Related]
2. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
3. Excretion patterns of pseudouridine and beta-aminoisobutyric acid in patients with tumours of the upper urinary tract.
Kvist E; Sjølin KE; Iversen J
Scand J Urol Nephrol; 1990; 24(4):287-92. PubMed ID: 2274753
[TBL] [Abstract][Full Text] [Related]
4. Urinary pseudouridine as a biochemical marker in the diagnosis and monitoring of primary hepatocellular carcinoma.
Tamura S; Fujioka H; Nakano T; Amuro Y; Hada T; Nakao N; Higashino K
Am J Gastroenterol; 1988 Aug; 83(8):841-5. PubMed ID: 2456010
[TBL] [Abstract][Full Text] [Related]
5. [The clinical significance of pseudouridine determination of the urine in children and adolescents].
Graf N; Bach K; Frisch B; Haas HJ; Sitzmann FC
Klin Padiatr; 1989; 201(3):154-62. PubMed ID: 2739340
[TBL] [Abstract][Full Text] [Related]
6. Pseudouridine: a modified nucleoside as biological marker in malignant lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1983; 6(1-2):293-6. PubMed ID: 6883387
[TBL] [Abstract][Full Text] [Related]
7. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of urinary and serum pseudouridine in diagnosis and monitoring of primary liver cancer.
Tu Z; Xu S; Wu M
Chin Med J (Engl); 1995 Mar; 108(3):204-8. PubMed ID: 7796629
[TBL] [Abstract][Full Text] [Related]
9. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
10. Pseudouridine and beta-aminoisobutyric acid excretion in urine: diagnostic and prognostic value.
Kvist E; Sjølin KE
Scand J Urol Nephrol; 1990; 24(4):283-5. PubMed ID: 2274752
[TBL] [Abstract][Full Text] [Related]
11. [Molecular and immunological approach to hematological disease: detection and analysis of intracellular modified nucleosides by flow cytometry].
Hoshino A; Honda I; Ishimori A; Itoh K; Mizugaki M; Nose M
Rinsho Byori; 1990 Jul; 38(7):756-64. PubMed ID: 2402080
[TBL] [Abstract][Full Text] [Related]
12. Pyrimidine nucleoside, pseudouridine, and modified nucleoside excretion by growing and resting fibroblasts.
Uziel M; Selkirk JK
J Cell Physiol; 1979 May; 99(2):217-22. PubMed ID: 457787
[TBL] [Abstract][Full Text] [Related]
13. Urinary pseudouridine and beta-aminoisobutyric acid in patients with low grade urothelial tumours. Relations between excretion and tumour recurrence.
Nyholm KK; Sjolin KE; Wolf H; Hammer M; Knudsen J; Stahl D; Nielsen HR
Biomedicine; 1976 May; 25(3):85-7. PubMed ID: 949520
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of beta-aminoisobutyrate and pseudouridine in acute and chronic myeloid leukemia.
Nielsen HR; Killmann SA
J Natl Cancer Inst; 1983 Nov; 71(5):887-91. PubMed ID: 6580488
[TBL] [Abstract][Full Text] [Related]
15. Pseudouridine excretion in patients with psoriasis.
Clemmensen OJ; Kieffer M; Sjølin KE
Acta Derm Venereol; 1987; 67(4):310-4. PubMed ID: 2445149
[TBL] [Abstract][Full Text] [Related]
16. Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia.
Heldman DA; Grever MR; Miser JS; Trewyn RW
J Natl Cancer Inst; 1983 Aug; 71(2):269-73. PubMed ID: 6576186
[TBL] [Abstract][Full Text] [Related]
17. [Interrelationship of pseudouridine and transfer RNA metabolic disorders in thermal injury].
Salomatin VV; Efimenko GP; Kamilov FKh; Lifshits RI
Vopr Med Khim; 1977; 23(5):642-6. PubMed ID: 595499
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of o-Nitroanisole (CAS No. 91-23-6) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 May; 416():1-482. PubMed ID: 12616295
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of modified nucleosides in chronic myelogenous leukemia.
Heldman DA; Grever MR; Speicher CE; Trewyn RW
J Lab Clin Med; 1983 May; 101(5):783-92. PubMed ID: 6572681
[TBL] [Abstract][Full Text] [Related]
20. Pseudouridine excretion and transfer RNA primers for reverse transcriptase in tumors of retroviral origin.
Esposito F; Russo T; Ammendola R; Duilio A; Salvatore F; Cimino F
Cancer Res; 1985 Dec; 45(12 Pt 1):6260-3. PubMed ID: 2415241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
